Journals / Koşuyolu Heart Journal / 2022 / Cilt: 25 - Sayı: 1

Prognostic Impact of Modified Glasgow Prognostic Score in Patients with Heart Failure with Mildly Reduced Ejection Fraction

Pages
6–13
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mGPS was calculated and, its association with overall survival was determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Inflammation and malnutrition may trigger heart failure development and progression (HF).
📊
Key Findings & Data:Patients and Methods: Patients with HFmrEF admitted to our outpatient clinic between January 2016 and January 2020 were enrolled.
💡
Conclusion & Impact:The mGPS was calculated and, its association with overall survival was determined.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Heart failure · ejection fraction · heart

Abstract

Introduction: Inflammation and malnutrition may trigger heart failure development and progression (HF). However, the relationship of the modified Glasgow prognostic score (mGPS), which is derived from C-reactive protein and albumin with mildly reduced ejection fraction HF (HFmrEF), is not well-known. We aimed to determine whether the modified Glasgow prognostic score (mGPS) is helpful for the prediction of all-cause mortality in patients with HFmrEF. Patients and Methods: Patients with HFmrEF admitted to our outpatient clinic between January 2016 and January 2020 were enrolled. All-cause mortality was defined as the primary endpoint. The mGPS was calculated and, its association with overall survival was determined. Results: Data were analyzed for 259 patients. The mGPS≤ 1 in 172 (66%), and 2 in 87 (34%) patients, respectively. Higher mGPS was related to worse results of routine biomarkers associated with prognosis, especially NT-proBNP [777 (112-4564) pg/mL vs. 350 (65-3521) pg/mL, respectively, p

🔖

Cite This Article

Çağdaş, M., Bezgin, T., Çelik, A. İ., Karagöz, A., Baytuğan, N. Z., Karakoyun, S., Kaymaz, C. (2022). Prognostic Impact of Modified Glasgow Prognostic Score in Patients with Heart Failure with Mildly Reduced Ejection Fraction. Koşuyolu Heart Journal, Cilt: 25 - Sayı: 1, 6–13. https://ajindex.com/articles/575849

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021
  2. 42(36):3599-726. [Crossref] 2. Freeman AM, Morris PB, Barnard N, Esselstyn CB, Ros E, Agatston A, et al. Trending cardiovascular nutrition controversies. J Am Coll Cardiol 2017
  3. 69(9):1172-87. [Crossref] 3. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study. Circulation 2003
  4. 107(11):1486-91. [Crossref] 4. Cho A, Arfsten H, Goliasch G, Bartko PE, Wurm R, Strunk G, et al. The inflammation-based modified Glasgow prognostic score is associated with survival in stable heart failure patients. ESC Heart Fail 2020
  5. 7(2):654-62. [Crossref] 5. Sze S, Pellicori P, Zhang J, Clark AL. Malnutrition, congestion, and mortality in ambulatory patients with heart failure. Heart 2019
  6. [Crossref] 6. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013
  7. [Crossref] 7. Bolat I, Biteker M. Modified Glasgow prognostic score is a novel predictor of clinical outcome in heart failure with preserved ejection fraction. Scand Cardiovasc J 2020
  8. [Crossref] 8. Namiuchi S, Sugie T, Saji K, Takii T, Suda A, Kato A. The systemic inflammation-based Glasgow prognostic score as a prognostic factor in patients with acute heart failure. J Cardiovasc Med (Hagerstown) 2015
  9. 16(6):409-15. [Crossref] 9. Altay S, Gürdoğan M, Keskin M, Kardaş F, Çakır B. The inflammation-based glasgow prognostic score as a prognostic factor in patients with intensive cardiovascular care unit. Medicina (Kaunas) 2019
  10. 55(5):139. [Crossref] 10. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996
  11. 2(3):243-9. [Crossref] 11. Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res 2016
  12. [Crossref] 12. Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res 2012
  13. [Crossref] 13. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European